ADDED
As of March 2, 2026, the number of common shares outstanding was 127,044,356 .
Business Overview ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates ( ADCs ), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC.
Food and Drug Administration ( FDA ) and conditional approval from the European Commission, China National Medical Products Administration ( NMPA ) and Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy.
We are pursuing expansion of ZYNLONTA internationally, and into earlier lines of diffuse large B-cell lymphoma ( DLBCL ) through our LOTIS-5 confirmatory Phase 3 clinical trial (rituximab combination) and LOTIS-7 Phase 1b clinical trial (bispecific combination) as well as into indolent lymphomas, including marginal zone lymphoma ( MZL ) and follicular lymphoma ( FL ), through investigator-initiated trials ( IITs ) at leading institutions.
Headquartered in Lausanne (Biop le), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical development to manufacturing and commercialization.
Our Product and Pipeline The following table provides an overview of our current approved product and pipeline: In addition to the current approved product and pipeline above, IND-enabling activities for ADCT-241 (the Company s exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC) were completed at the end of 2025.
Our Strategy and Competitive Capabilities Our goal is to be a leading ADC company bringing meaningful therapies to patients in need by leveraging our decade-long experience in the ADC field, with multiple INDs, and a proven track record of success.
By leveraging our clinical development expertise and established commercial infrastructure, we are uniquely capable of expanding ZYNLONTA into earlier lines of DLBCL and indolent lymphomas as a single agent and in combination with other therapies.
ZYNLONTA has a manageable safety profile with no cytokine release syndrome ( CRS ) or Immune Effector Cell-Associated Neurotoxicity Syndrome ( ICANS ) and no cumulative irreversible toxicities reported in the LOTIS-2 trial.
ZYNLONTA offers accessibility for patients with a simple Q3W dosing with no Risk Evaluation and Mitigation Strategies ( REMS ) or in-patient stay requirements.
REMOVED
As of March 17, 2025, the number of common shares outstanding was 99,083,838 .
Market and Industry Data This Annual Report contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research.
Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
Business Overview ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates ( ADCs ).
The Company is advancing its proprietary ADC technology with the goal of transforming the cancer treatment paradigm for patients with hematologic malignancies and solid tumors.
We have a validated and differentiated technology platform with multiple payloads, linkers and conjugation chemistry, enabling the design of next-generation potent ADCs with an enhanced therapeutic index.
We are seeking to expand the label for our FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine) into new indications and earlier lines of therapy while pursuing our early-stage solid tumor programs.
We leverage our scientific and technical expertise and apply a disciplined approach to target selection to expand and advance our pipeline.
Our portfolio of ADCs utilizes our highly potent pyrrolobenzodiazepine ( PBD ) payload, a differentiated exatecan-based payload with a novel hydrophilic linker and a next generation ADC toolbox.
In our hematology program, our flagship product, ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.